CD30+ Lymphoproliferative Disorders of the Skin

Publication date: April 2017
Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 2
Author(s): Maxwell B. Sauder, John T. O'Malley, Nicole R. LeBoeuf

Teaser

Primary cutaneous CD30⁺ lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. pcALCL is characterized by a solitary red to violaceous nodule or tumor larger than 20 mm. LyP is benign, is limited to the skin, and self-resolves, with a 5-year survival rate of 100%; pcALCL is limited to the skin and responsive to directed therapies, with a 5-year survival rate of over 95%. Aggressive chemotherapeutic regimens should be avoided.


http://ift.tt/2oEhR0i